BetaShares Australian Ex-20 Portfolio Diversifier ETF (EX20) might be the best way to invest in ASX shares

BetaShares Australian Ex-20 Portfolio Diversifier ETF (ASX: EX20) could be the best way to invest in ASX shares.

Why investing in ASX shares is great

ASX shares have been one of the best performing assets over the long term. Businesses have the ability to generate good returns, re-invest for growth and pay out a dividend.

Australian companies have the added bonus of franking credits which can boost the dividend income paid to shareholders.

Over the long term, ASX shares can produce better returns than cash or bonds and pay better dividends than international shares. We get to invest in the businesses that we (probably) know and perhaps use every week. You may feel a better connection to your service provider if you also own shares of CBA (ASX: CBA), Woolworths (ASX: WOW) or Telstra (ASX: TLS).

So why not just invest in the biggest ASX ETFs?

There are some great ETFs that Aussies can buy which focus on the ASX. ETFs like BetaShares Australia 200 ETF (ASX: A200) and Vanguard Australian Shares Index ETF (ASX: VAS) can give exposure to the ASX 200 or ASX 300 for a very cheap fee of 0.07% of 0.10% respectively.

However, both of those ETFs are dominated by CSL (ASX: CSL), the big four ASX banks and BHP (ASX: BHP). That’s not very diversified. It defeats one of the best reasons for picking an ETF – diversification.

But the ASX does have some great shares, they just don’t make up a large weighting of the ASX.

That’s why I think BetaShares Australian Ex-20 Portfolio Diversifier ETF could be a solid idea. As the name may suggest, it excludes the shares in the ASX 20. The ASX 20 aren’t terrible businesses, but they are big companies with not much growth potential.

BetaShares Australian Ex-20 Portfolio Diversifier ETF’s largest holdings are shares like: Fortescue Metals Group (ASX: FMG), Brambles (ASX: BXB), Fisher & Paykel Healthcare (ASX: FPH), Sonic Healthcare (ASX: SHL), A2 Milk (ASX: A2M), ASX (ASX: ASX), Ramsay Health Care (ASX: RHC), Cochlear (ASX: COH), Insurance Australia Group (ASX: IAG) and APA (ASX: APA).

These shares (and the other 170 or so) have the potential outperform the main ASX ETFs over the long term with the stronger growth characteristics.

BetaShares Australian Ex-20 Portfolio Diversifier ETF isn’t even that much more expensive. Its annual management fee is only 0.25% per year. That’s cheaper than nearly all the active fund managers out there. It has a solid dividend yield too, thanks to high yield shares like Fortescue, the ETF’s trailing partially franked dividend yield is 5.7%.

Summary

I would rather invest in this ETF over the A200 ETF or the VAS ETF. I think the ASX has a lot of quality growth shares, I just don’t feel that the ASX 20 provides that – which is why the EX20 ETF is an appealing way to passively invest in ASX shares.

[ls_content_block id=”695″ para=”paragraphs”]

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report, and 24/7 access to the Rask community, for FREE by CLICKING HERE NOW or the button below.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.